NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment

Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment

CADTH Optimal Use Report, No. 8.1b

Clinical Review Authors: , , and . Economic Evaluation Authors: , , and . Patients’ Perspectives and Experiences Review Authors: and . Ethical Issues Analysis Author: ; Implementation Issues Analysis author: ; Research Information Specialist authors: and .

Author Information

The purpose of this HTA is to inform the policy questions through an assessment of the clinical effectiveness and safety, cost-effectiveness, patients’ perspectives and experiences, ethical issues, and implementation issues of minimally invasive glaucoma surgery devices and procedures for adults with glaucoma.

Contents

About the Series

CADTH Optimal Use Report
ISSN: 1927-0127

Dr. Cindy Hutnik has received funding from Allergan for research and for being on a user’s group panel, and from Medicus for writing articles or editorials and being on an expert panel on glaucoma management. The other authors declared no conflicts of interest relevant to this report.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.

Suggested citation:

Optimal use of minimally invasive glaucoma surgery: a health technology assessment. Ottawa: CADTH; 2019. (CADTH optimal use report; vol.8, no.1b).

Disclaimer: This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). This report contains a comprehensive review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared, and it was guided by expert input and advice throughout its preparation.

The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report

CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.

Production of this report is made possible through a financial contribution from Health Canada.

Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.

Copyright © CADTH. This report may be reproduced for non-commercial purposes only and provided that appropriate credit is given to CADTH.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK543901PMID: 31305970

Views

Other titles in this collection

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...